---
title: "Taltz (ixekizumab) in plaque psoriasis: Safety questions"
description: "Safety questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Safety evidence, Warnings, and Administration reactions. Questions: What are the most common side effects of Taltz for plaque psoriasis? What are the long-term side effects of Taltz for plaque psoriasis? Does Taltz increase the risk of infections? Does Taltz cause yeast infections (candidiasis)? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Safety questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Safety questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications: Safety](https://www.evicenter.com/medical-information/taltz/safety).

## Side effects

<a id="taltz-side-effects"></a>

### What are the most common side effects of Taltz for plaque psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. (6.1)”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Most%20common%20%28%E2%89%A51%25%29%20adverse%20reactions,nausea%2C%20and%20tinea%20infections.%20%286.1%29)

> “In the 12-week, placebo-controlled period, adverse events occurred in 58% of the TALTZ Q2W group (2.5 per subject-year of follow-up) compared with 47% of the placebo group (2.1 per subject-year of follow-up). Serious adverse events occurred in 2% of the TALTZ group (0.07 per subject-year of follow-up), and in 2% of the placebo group (0.07 per subject-year of follow-up).”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20the%2012%2Dweek%2C%20placebo%2Dcontrolled%20period%2C,%280.07%20per%20subject%2Dyear%20of%20follow%2Dup%29.)

> “ADVERSE REACTIONS AND INFECTIONS1 through Week 12
>
> Taltz 80 mg every 2 weeks (n=1167)
> Placebo (n=791)
> The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild to moderate in severity and did not lead to discontinuation of Taltz.
>
> Adverse reactions that occurred in ≥1% of Taltz patients and more frequently than with placebo
>
> ADVERSE REACTIONS
> 17%, Injection site reactions, PBO = 3%
> 14%, Upper respiratory tract infections*, PBO = 13%
> 2%, Nausea, PBO = 1%
> 2%, Tinea infections, PBO <1%
>
> <sup>*</sup>Upper respiratory tract infections include nasopharyngitis and rhinovirus infection.
> PBO=placebo.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=ADVERSE%20REACTIONS%20AND%20INFECTIONS1%20through,PBO%3Dplacebo.)

> “Adverse reactions that occurred at rates less than 1% in the TALTZ group and more frequently than in the placebo group during the 12-week induction period included rhinitis, oral candidiasis, urticaria, influenza, conjunctivitis, inflammatory bowel disease, and angioedema.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Adverse%20reactions%20that%20occurred%20at%20rates,inflammatory%20bowel%20disease%2C%20and%20angioedema.)

<a id="taltz-yeast-infections"></a>

### Does Taltz cause yeast infections (candidiasis)?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the TALTZ group than in the placebo group.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Upper%20respiratory%20tract%20infections%2C%20oral,than%20in%20the%20placebo%20group.)

> “Adverse reactions that occurred at rates less than 1% in the TALTZ group and more frequently than in the placebo group during the 12-week induction period included rhinitis, oral candidiasis, urticaria, influenza, conjunctivitis, inflammatory bowel disease, and angioedema.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Adverse%20reactions%20that%20occurred%20at%20rates,inflammatory%20bowel%20disease%2C%20and%20angioedema.)

> “Infections: bacterial, viral, and fungal opportunistic infections, including cryptococcal meningoencephalitis, esophageal and disseminated mucocutaneous candidiasis, pulmonary tuberculosis, toxoplasmosis, varicella zoster virus reactivation, cytomegalovirus colitis, pulmonary aspergillosis.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Infections%3A%20bacterial%2C%20viral%2C%20and%20fungal,reactivation%2C%20cytomegalovirus%20colitis%2C%20pulmonary%20aspergillosis.)

Note: The last passage lists postmarketing reports from the Prescribing Information.

<a id="taltz-blood-counts"></a>

### Can Taltz cause low white blood cell or platelet counts?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Over the entire treatment period (Weeks 0 to 60), neutropenia occurred in 11% of subjects treated with TALTZ (0.24 per subject-year of follow-up) compared to 3% of subjects treated with placebo (0.14 per subject-year of follow-up). In subjects treated with TALTZ, the incidence rate of neutropenia during Weeks 13 to 60 was lower than the incidence rate during Weeks 0 to 12.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Over%20the%20entire%20treatment%20period%20%28Weeks%200%20to%2060%29%2C%20neutropenia,during%20Weeks%200%20to%2012.)

> “In the 12-week, placebo-controlled period, neutropenia ≥ Grade 3 (<1,000 cells/mm3) occurred in 0.2% of the TALTZ group (0.007 per subject-year of follow-up) compared to 0.1% of the placebo group (0.006 per subject-year of follow-up). The majority of cases of neutropenia were either Grade 2 (2% for TALTZ 80 mg Q2W versus 0.3% for placebo; ≥1,000 to <1,500 cells/mm3) or Grade 1 (7% for TALTZ 80 mg Q2W versus 3% for placebo; ≥1,500 cells/mm3 to ˂2,000 cells/mm3). Neutropenia in the TALTZ group was not associated with an increased rate of infection compared to the placebo group.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20the%2012%2Dweek%2C%20placebo%2Dcontrolled%20period%2C%20neutropenia,compared%20to%20the%20placebo%20group.)

> “Ninety eight percent of cases of thrombocytopenia were Grade 1 (3% for TALTZ 80 mg Q2W versus 1% for placebo; ≥75,000 cells/mm3 to <150,000 cells/mm3). Thrombocytopenia in subjects treated with TALTZ was not associated with an increased rate of bleeding compared to subjects treated with placebo.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Ninety%20eight%20percent%20of%20cases,to%20subjects%20treated%20with%20placebo.)

<a id="taltz-antidrug-antibodies"></a>

### Does Taltz cause anti-drug antibodies in plaque psoriasis?

> “By Week 12, approximately 9% of adult subjects treated with TALTZ every 2 weeks developed antibodies to ixekizumab. Approximately 22% of subjects treated with TALTZ at the recommended dosing regimen developed antibodies to ixekizumab during the 60-week treatment period. The clinical effects of antibodies to ixekizumab are dependent on the antibody titer; higher antibody titers were associated with decreasing drug concentration and clinical response.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=By%20Week%2012%2C%20approximately%209%25,drug%20concentration%20and%20clinical%20response.)

> “Of the adult subjects who developed antibodies to ixekizumab during the 60-week treatment period, approximately 10%, which equates to 2% of subjects treated with TALTZ at the recommended dosing regimen, had antibodies that were classified as neutralizing. Neutralizing antibodies were associated with reduced drug concentrations and loss of efficacy.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Of%20the%20adult%20subjects%20who,concentrations%20and%20loss%20of%20efficacy.)

> “In pediatric psoriasis subjects treated with ixekizumab at the recommended dosing regimen up to 12 weeks, 21 subjects (18%) developed anti-drug antibodies, 5 subjects (4%) had confirmed neutralizing antibodies associated with low drug concentrations. No conclusive evidence could be obtained on the potential association of neutralizing antibodies and clinical response and/or adverse events due to small number of pediatric subjects in the study.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20pediatric%20psoriasis%20subjects%20treated,pediatric%20subjects%20in%20the%20study.)

## Safety evidence

<a id="taltz-long-term-side-effects"></a>

### What are the long-term side effects of Taltz for plaque psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “TALTZ PSORIASIS CLINICAL TRIALS”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=TALTZ%20PSORIASIS%20CLINICAL%20TRIALS)

> “More than 6,800 patients across 15 clinical trials”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=More%20than%206%2C800%20patients%20across%2015%20clinical%20trials)

> “ADVERSE EVENTS OF SPECIAL INTEREST: INCIDENCE RATES PER 100 PYS
>
> Table Description
>
> Total PY=17,599
>
> Year 1 PY=5688
>
> Year 2 PY=3390
>
> Year 3 PY=3108 (n)
>
> Year 4 PY=2882 (n)
>
> Year 5 PY=2375 (n)
>
> Serious infections	1.3	1.3	1.4	1.7	1.4	1.3
> Candida infections	1.9	3.2	2.2	2.1	2.3	2.0
> Hypersensitivity
> (non-anaphylaxis)	5.1	9.8	5.0	4.4	4.2	3.5
> Hypersensitivity
> (potential anaphylaxis<sup>**</sup>)	0.1	0.2	0.1	0.0 (0)	0.0 (0)	0.0 (0)
> Crohn's disease<sup>††</sup>	0.1	0.1	0.1	0.0 (1)	0.0 (1)	0.1
> Ulcerative colitis<sup>††</sup>	0.1	0.2	0.1	0.0 (1)	0.0 (0)	0.1
> Malignancy-related (Nonmelanoma skin cancer)	0.3	0.5	0.2	0.4	0.2	0.2
> Malignancy-related (Malignancies excluding NMSCs)	0.5	0.5	0.6	0.5	0.6	0.6
> Injection site reactions	5.5	16.1	4.2	2.2	2.3	1.7
>
> <sup>**</sup>After review of potential cases, no confirmed cases of anaphylaxis in clinical trials.<sup>10</sup>
> <sup>††</sup>Data on all suspected IBD, as identified by events potentially indicative of ulcerative colitis or Crohn’s disease, were adjudicated according to EPIMAD criteria by an external clinical review committee of gastroenterologists with IBD expertise.
>
> When incidence rates equal 0.0, the n value is added; n=number of events.
>
> The average and median Taltz exposure durations were 996.7 days and 718 days, respectively.<sup>11</sup>
>
> Certain adverse events, such as malignancy, require longer observation periods and larger patient exposure to ascertain risk. In the reported safety population of the psoriasis clinical trials, not all patients received the recommended dosing regimen consistent with the FDA-approved label.
>
> PY=patient-year; NMSC=nonmelanoma skin cancer; IBD=inflammatory bowel disease; EPIMAD=Registre Epidemiologique des Maladies de l’Appareil Digestif.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=ADVERSE%20EVENTS%20OF%20SPECIAL%20INTEREST%3A,des%20Maladies%20de%20l%E2%80%99Appareil%20Digestif.)

> “During the maintenance period (Weeks 13 to 60), adverse events occurred in 80% of subjects treated with TALTZ (1.0 per subject-year of follow-up) compared to 58% of subjects treated with placebo (1.1 per subject-year of follow-up). Serious adverse events were reported in 4% of subjects treated with TALTZ (0.05 per subject-year of follow-up) and none in the subjects treated with placebo.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=During%20the%20maintenance%20period%20%28Weeks,the%20subjects%20treated%20with%20placebo.)

> “Over the entire treatment period (Weeks 0 to 60), adverse events were reported in 67% of subjects treated with TALTZ (1.4 per subject-year of follow-up) compared to 48% of subjects treated with placebo (2.0 per subject-year of follow-up). Serious adverse events were reported in 3% of subjects treated with TALTZ (0.06 per subject-year of follow-up), and in 2% of subjects treated with placebo (0.06 per subject-year of follow-up).”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Over%20the%20entire%20treatment%20period,%280.06%20per%20subject%2Dyear%20of%20follow%2Dup%29.)

Note: The table gives incidence rates per 100 patient-years for the total exposure period and then for Years 1 through 5, in the order of the header lines. Above the table, the Taltz HCP adult psoriasis page describes the pooled population as more than 6,800 patients across 15 clinical trials; its safety summary on the same page describes the long-term safety data as an integrated data set of 17 phase 1, 2, 3, and 4 studies in adults with moderate to severe plaque psoriasis, with a March 2022 cutoff.

## Warnings

<a id="taltz-infections"></a>

### Does Taltz increase the risk of infections?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “TALTZ may increase the risk of infection. In clinical trials in adult patients with plaque psoriasis, the TALTZ group had a higher rate of infections than the placebo group (27% vs. 23%). Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the TALTZ group than in the placebo group. A similar increase in risk of infection was seen in placebo-controlled trials in patients with pediatric psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis [see Adverse Reactions (6.1)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=TALTZ%20may%20increase%20the%20risk,spondyloarthritis%20%5Bsee%20Adverse%20Reactions%20%286.1%29%5D.)

> “In the postmarketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors including TALTZ. Instruct patients treated with TALTZ to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TALTZ until the infection resolves.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20the%20postmarketing%20setting%2C%20serious,TALTZ%20until%20the%20infection%20resolves.)

> “In the 12-week, placebo-controlled period of the clinical trials in plaque psoriasis, infections occurred in 27% of subjects treated with TALTZ (1.2 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.4% of subjects treated with TALTZ (0.02 per subject-year of follow-up) and in 0.4% of subjects treated with placebo (0.02 per subject-year of follow-up) [see Warnings and Precautions (5.1)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20the%2012%2Dweek%2C%20placebo%2Dcontrolled%20period%20of,%5Bsee%20Warnings%20and%20Precautions%20%285.1%29%5D.)

<a id="taltz-ibd"></a>

### Can Taltz cause Crohn's disease or ulcerative colitis (IBD)?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Patients treated with TALTZ may be at increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ group than the placebo control group [see Adverse Reactions (6.1)]. During TALTZ treatment, monitor for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue TALTZ and initiate appropriate medical management.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Patients%20treated%20with%20TALTZ%20may,and%20initiate%20appropriate%20medical%20management.)

> “In adult subjects with plaque psoriasis, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than the placebo group (0%) during the 12-week, placebo-controlled period in clinical trials [see Warnings and Precautions (5.5)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20adult%20subjects%20with%20plaque,%5Bsee%20Warnings%20and%20Precautions%20%285.5%29%5D.)

## Administration reactions

<a id="taltz-injection-site-reactions"></a>

### How common are injection site reactions with Taltz?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “17%, Injection site reactions, PBO = 3%”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=17%25%2C%20Injection%20site%20reactions%2C%20PBO%20%3D%203%25)

> “The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild-to-moderate in severity and did not lead to discontinuation of TALTZ.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=The%20most%20frequent%20injection%20site,lead%20to%20discontinuation%20of%20TALTZ.)

Note: The 17% and 3% rates are for Taltz 80 mg every 2 weeks and placebo through Week 12 in adults with moderate-to-severe plaque psoriasis, as presented on the Taltz HCP adult psoriasis page.

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines)
